NXC828 is a novel HIF-1α inhibitor being developed for the treatment of wet age-related macular degeneration (wet-AMD) as an eye drop formulation. Current standard treatments of wet-AMD are anti-VEGF intravitreal injections which entail a variety of issues such as injection-associated side effects, fear of injection and high medical costs. An eye drop formulation may be the solution to alleviating these unmet medical needs by allowing patients to self-administer the medication at anytime and anywhere while avoiding injection-associated side effects.
| Indication | Wet-AMD |
|---|---|
| Route of Administration | Eye drop |
| Development Status | Pre-clinical |
| Mechanism of Action | HIF-1α inhibitor |
| Highlight |
|
